Scholars Central

Conference abstractPublished 25 Jun 2018

Common allergic reactions

Authors: Ravi Gutta

Mediclinic City Hospital, UAE

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Incidence of allergies have gone up all over the world. Drug allergies, anaphylaxis, food allergy and urticaria are the most common forms of allergic reactions and pose a clinical challenge for nurse practitioners and as well both outpatient and inpatient nurses as they encounter on day to day basis in clinical setting. As allergies are very sub specialized disease diathesis, I want to present core clinical concepts for nurse practitioners to approach the common allergic conditions with standard of care, and evidence based clinical approach for evaluation and management of them. In the current era of polypharmacy, drug allergic reactions are very common and present a great challenge for nurse practitioners. 10% of hospitalized patients may develop beta lactam drug allergy. I will present core clinical concepts based on drug allergy practice parameters update by American academy of allergy, asthma and immunology as a model to have thorough understanding on how to approach drug allergy, how to evaluate for risk assessment for future reactions, clinical approach to patients with drug allergy. Anaphyalxis is considered as killer allergy. Nurse practitioners will encounter anaphylaxis patients in both inpatient and outpatient settings. I will present updated Anaphyalxis practice parameter by AAAAI recommended evidence based clinical guidelines for evaluation and management of anaphylaxis. In incidence of food allergy has gone up by 400% in last decade, raising alarm bells. There is huge void in understanding and clinical approach to food allergy clinical evaluation and management among nurse practitioners. I will present NIAID food allergy guidelines recommended evidence based clinical approach to food allergy. 1% General population encounter chronic urticarial in their life time. For past 20 years there has been on management update for this condition beyond immunosuppressive therapy. In 2014 US FDA approved Omalizumab ( Xolair) biological therapy for management of urticarial. I will present rationale, pathophysiology and evidence for such recommendation for nurse practitioners to have better understanding and can start managing these patients in OP setting.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Nursing & Care.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nursing & Care
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Ravi Gutta”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels